Talk:Esmethadone: Difference between revisions – Wikipedia

This edit request by an editor with a conflict of interest has now been answered.

Current information to be corrected:
“As of December 2024, phase 3 clinical trials for this indication were discontinued due to the potential of eye disorders, mitochondrial disorders, neuropathic pain and Rett syndrome.”

This sentence is unclear and incomplete.

Proposed replacement text:
The Esmethadone drug development program was returned to the original licensors and inventors, Charles Inturrisi and Paolo Manfredi, by Relmada Therapeutics on July 7, 2025.

Levomecor Inc., a U.S.-based biotech company, has since taken over the development of esmethadone for the adjunctive treatment of major depressive disorder.

Two esmethadone Phase 3 trials that were terminated early in December 2024 did not meet the primary endpoint at Day 28. However, these trials indicated rapid Day 7 antidepressant efficacy, supporting the continued development of esmethadone for the adjunctive treatment of major depressive disorder.

Supporting sources:
1. Relmada Therapeutics SEC filing, July 10, 2025 – [1](https://www.relmada.com/for-investors/sec-filings?page=2##document-10649-0001213900-25-062803-2)
2. Levomecor official website – [2](https://www.levomecor.com/)
3. WCP 2025 ePoster – [3](https://static1.squarespace.com/static/6241c23c0cd52f592d262c79/t/68e24ffe5c87c717e947726f/1759662078030/WCP25+ePoster.pdf)
4. Dextromethadone – Cornell University / Relmada Therapeutics – AdisInsight (Springer). Levomecor (talk) 16:19, 7 November 2025 (UTC)[reply]

 Go ahead: I have reviewed these proposed changes and suggest that you go ahead and make the proposed changes to the page. NotJamestack (talk) 19:02, 7 November 2025 (UTC)[reply]

Proposer has been soft blocked for username. Also the sources are all primary sources, not strong enough to be MEDRS-compliant given that this is a medical topic. Lavalizard101 (talk) 19:47, 7 November 2025 (UTC)[reply]

Thank you for the feedback.

I’ve changed my username to comply with COI and username policies.

AdisInsight (Springer) has now updated their entry, providing a secondary source that supports the factual update.

I’m happy to let a neutral editor review or adjust the wording if needed. Chiaralm95 (talk) 20:33, 12 November 2025 (UTC)[reply]

Please change:

“As of December 2024, phase 3 clinical trials for this indication were discontinued due to the potential of eye disorders, mitochondrial disorders, neuropathic pain and Rett syndrome.”

to:

“The esmethadone drug development program was returned to the original licensors and inventors, Charles Inturrisi and Paolo Manfredi, by Relmada Therapeutics on July 7, 2025.

Levomecor Inc., a U.S.-based biotech company, has since taken over the development of esmethadone for the adjunctive treatment of major depressive disorder.

Two esmethadone Phase 3 trials that were terminated early in December 2024 did not meet the primary endpoint at Day 28. However, these trials indicated rapid Day 7 antidepressant efficacy, supporting the continued development of esmethadone for the adjunctive treatment of major depressive disorder.”

Supporting sources:

1. Relmada Therapeutics SEC filing, July 10, 2025

2. Levomecor official website

3. WCP 2025 ePoster

4. Dextromethadone – Cornell University / Relmada Therapeutics – AdisInsight (Springer)

I have a potential COI, so I am requesting that an uninvolved editor make this edit, thank you.

Chiaralm95 (talk) 10:33, 19 November 2025 (UTC)[reply]

 Not done: The changes are not supported by neutral, independent, reliable sources. Please provide reliable sources that support the change you want to be made.  Please provide links to the sources. NotJamestack (✉️|📝) 12:28, 19 November 2025 (UTC)[reply]